Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma
Abstract Background The third-generation epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have shown significant therapeutic effects on patients with non-small cell lung carcinoma (NSCLC) who carry active EGFR mutations, as well as those who have developed acquired resistance...
Main Authors: | Yuting Meng, Xixi Qian, Li Zhao, Nan Li, Shengjie Wu, Baoan Chen, Tong Sun, Xuerong Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-021-01914-y |
Similar Items
-
The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
by: Yasushi Taniguchi
Published: (2016-11-01) -
The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats
by: Jérôme Piquereau, et al.
Published: (2019-03-01) -
Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
by: Archit Trivedi, et al.
Published: (2020-03-01) -
Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
by: Yanli Sun, et al.
Published: (2021-01-01) -
Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
by: Jiacheng Lai, et al.
Published: (2021-09-01)